Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Queensland Health
Citi
Boehringer Ingelheim
Baxter

Generated: March 18, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BREVIBLOC

« Back to Dashboard

Clinical Trials for Brevibloc

Trial ID Title Status Sponsor Phase Summary
NCT01114971 Labetalol and Esmolol: Vital Signs and Post Operative Pain Management Recruiting Cedars-Sinai Medical Center Phase 4 This study proposes to investigate the effects of labetalol or esmolol on managing the vital signs (like blood pressure and heart rate) during surgery, on pain management, and on the later recovery after surgery. It will also assess the cost-effectiveness of Labetalol and esmolol for outpatient surgery.
NCT01179113 Esmolol Infusion During Laminectomy: Effect on Quality of Recovery Terminated Cedars-Sinai Medical Center Phase 4 The purpose of this study is to evaluate the effects of esmolol, a drug which is commonly administered during surgery to help control blood pressure and heart rate, on postoperative pain levels and requirements for pain medication.
NCT01208402 Esmolol for Treatment of Perioperative Tachycardia Terminated Baxter Healthcare Corporation Phase 3 The purpose of this study is to find out if Esmolol is a safe and effective alternative treatment compared to standard treatment using a long acting beta blocker drug, in controlling abnormal heart rate before, during and immediately after surgery.
NCT01208402 Esmolol for Treatment of Perioperative Tachycardia Terminated Duke University Phase 3 The purpose of this study is to find out if Esmolol is a safe and effective alternative treatment compared to standard treatment using a long acting beta blocker drug, in controlling abnormal heart rate before, during and immediately after surgery.
NCT01232400 Study to Evaluate Esmolol (Brevibloc) to Manage Cardiac Function in Patients With Subarachnoid Hemorrhage Withdrawn University of Michigan N/A The purpose of this study is to evaluate the clinical effect of esmolol treatment on cardiac function and electrophysiology; to assess the effects of esmolol treatment on serum adrenergic and cardiac biomarkers; to explore the safety of esmolol treatment shortly after subarachnoid hemorrhage (SAH). Patients will be followed for a maximum of 1 month after the index SAH. The primary outcome will be change in systolic function - ejection fraction by Simpson's rule (baseline versus Day 7 +/- 2 after SAH).
NCT01343329 Controlling Hyperadrenergic Activity in Neurologic Injury Unknown status Johns Hopkins University Phase 1/Phase 2 Traumatic brain injury (TBI) is frequently associated with a hyperadrenergic state accompanied by elevated levels of plasma catecholamines. In its more severe presentation, the hyperadrenergic state presents as dysautonomia, which is characterized by paroxysmal alteration in vital signs, including tachycardia. The investigators hypothesize that intravenous (IV) esmolol is as effective at controlling heart rate in hyperadrenergic states as oral propranolol, which is the standard of care. Our primary endpoint is efficacy of IV esmolol vs a PRN regimen of intermittent B-blockade in controlling heart rate below a pre-specified level (< 100 bpm) after Traumatic Brain Injury (TBI). Heart rates will be recorded continuously as well as hourly.
NCT01628562 A Comparison of the Perioperative Hemodynamic Effects of Remifentanil and Esmolol in Intracranial Surgery Completed Diskapi Teaching and Research Hospital Phase 4 It was hypothesized that the use of esmolol as an alternative to remifentanil with sevoflurane inhalation anesthesia during intracranial surgery, could provide better hemodynamic conditions and cause lesser side effects in the perioperative period. It was the main objective of this study to compare the effect of esmolol and remifentanil on the incidence of tachycardia and hypertension and the intraoperative fentanyl consumption. The comparison of postoperative troponine I and creatine phosphokinase levels and EKG changes were the secondary objectives.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Brevibloc

Condition Name

Condition Name for Brevibloc
Intervention Trials
Septic Shock 3
Overdose of Beta-adrenergic Blocking Drug 1
High-risk, Non-cardiovascular Surgeries 1
Myocardial Reperfusion Injury 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Brevibloc
Intervention Trials
Shock, Septic 3
Shock 3
Tachycardia 2
Reperfusion Injury 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Brevibloc

Trials by Country

Trials by Country for Brevibloc
Location Trials
United States 7
Brazil 6
Turkey 3
China 1
France 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Brevibloc
Location Trials
California 2
Utah 1
Maryland 1
Michigan 1
Ohio 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Brevibloc

Clinical Trial Phase

Clinical Trial Phase for Brevibloc
Clinical Trial Phase Trials
Phase 4 7
Phase 3 1
Phase 2 3
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Brevibloc
Clinical Trial Phase Trials
Recruiting 6
Unknown status 3
Terminated 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Brevibloc

Sponsor Name

Sponsor Name for Brevibloc
Sponsor Trials
Baxter Healthcare Corporation 2
Cedars-Sinai Medical Center 2
Beth Israel Deaconess Medical Center 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Brevibloc
Sponsor Trials
Other 17
Industry 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Citi
US Army
US Department of Justice
Moodys
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.